Obstetrics-Gynecology & Women's Health

Cases of uterine sarcoma in women receiving tamoxifen citrate (Nolvadex, AstraZeneca) have prompted a "Dear Health Professional" letter, black-box warnings on labeling, and publication of a letter to the editor in the New England Journal of Medicine from FDA officials.

Genetic researchers promise countless improvements in the delivery of care due the development of new information and clues to genetic mutations.

The ruckus over designer babies, human cloning and genetic discrimination has colored much of the debate and perception of genetic services, but the discipline is gaining momentum as research propels new tests to determine the susceptibility to more common diseases, as well as a slew of rare ones.

NME:Once monthly IM injection; treats metastatic breast cancer after tamoxifen fails

Medications currently available to treat osteoporosis slow the rate of bone loss primarily by reducing bone resorption. The purported advantage of the anabolic agent teriparatide is that it actually promotes new bone growth. Clinical trials have shown the drug to be effective for vertebral fracture prevention in postmenopausal women at high risk. Additional evidence is accumulating to support teriparatide's use in other populations (including men) with osteoporosis. This injectable is likely to receive FDA approval in the second half of this year.

Emerging data are continually refining our understanding of the risks and benefits of hormone replacement therapy (HRT) in postmenopausal women. This review assesses the current state of evidence on these various risks and benefits, concluding with an outline of what's established and where varying degrees of uncertainty remain. Algorithms for use of HRT for several established indications are featured.

Health plans demand more information to gauge real value of new pharmaceuticals.

New combination, NME as component: Weekly contraceptive skin patch

NME: COX-2 inhibitor for rheumatoid arthritis, osteoarthritis, and dysmenorrhea

Perhaps the greatest criticism leveled at America's healthcare system is the fact that millions of people have no healthcare insurance at all. Our physicians are among the best trained in the world, and the equipment and technology they work with is state of the art. But those things are meaningless to patients who fall between the cracks of the system and can't access that care.

Current estimates indicate that overactive bladder is a widespread disorder. Yet, these figures only capture people willing to admit to symptoms.

New Formulations/Combinations: Hormonal vaginal contraceptive ring

news brief

Reducing the amount of fat in the blood is the key weapon against heart disease, and the battle plan recently changed.

The World Health Organization projects that in less than 20 years, depression will be the leading cause of disability in women worldwide.

New Indication: Combination use with docetaxel for breast cancer; new black box

New Indication: Oral contraceptive approved for acne

An interview with Helen Darling, president, Washington Business Group on Health.

News brief.

Breast cancer screening.

News brief.

News brief.

News brief.

News brief.

Forget the taboo. Sexually transmitted diseases are costing American employers just as much as more socially acceptable medical conditions. A panel of experts from the public and private sectors suggests actions.

News brief.

Depression is a common, debilitating and costly condition. These programs offer standards for comparison with your current behavioral health provider.

News brief.

The state of the nation's health care system.

Excellence in management, not unbridled spending, reduces medical error rates at Solucient&s 100 Top Hospitals. Find out what happens when hospitals develop sound business sense.